Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(R) therapy: A case report.

Please use this identifier to cite or link to this item: https://doi.org/10.1002/ccr3.2928

Full metadata record

DC Field	Value	Language
dc.contributor.author	Pumpure, Elizabete	-
dc.contributor.author	Dručka, Eva	-
dc.contributor.author	Kigitoviča, Dana	-
dc.contributor.author	Meškauskas, Raimundas	-
dc.contributor.author	Isajevs, Sergejs	-
dc.contributor.author	Nemiro, Ineta	-
dc.contributor.author	Rasa, Agnija	-
dc.contributor.author	Olmane, Evija	-
dc.contributor.author	Zablocka, Tatjana	-
dc.contributor.author	Alberts, Pēteris	-
dc.contributor.author	Doniņa, Simona	-
dc.date.accessioned	2022-01-19T09:20:12Z	-
dc.date.available	2022-01-19T09:20:12Z	-
dc.date.issued	2020-05-22	-
dc.identifier.uri	https://dspace.rsu.lv/jspui/handle/123456789/7229	-
dc.description.abstract	Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression-free survival are good.	en_US
dc.language.iso	en	en_US
dc.relation.ispartof	Clinical Case Reports, 8(8), 1538-1543	en_US
dc.rights	info:eu-repo/semantics/openAccess	en_US
dc.subject	ECHO-7 virus	en_US
dc.subject	melanoma	en_US
dc.subject	oncology	en_US
dc.subject	oncolytic virus	en_US
dc.subject	Rigvir	en_US
dc.subject	uterine cervix	en_US
dc.title	Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(R) therapy: A case report.	en_US
dc.type	Article	en_US
dc.identifier.doi	https://doi.org/10.1002/ccr3.2928	-
Appears in Collections:	Publications

Files in This Item:

File	Description	Size	Format
Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy A case report.pdf		1.22 MB	Adobe PDF	View/Open